GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
| Business Activity | PASS |
| Debt Ratio (0.00%) | PASS |
| Cash Ratio (0.19%) | PASS |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | PASS |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-06 | -0.32 | Pending | -- |
| 2026-05-14 | -0.26 | -0.31 | -17.7% |
| 2026-03-05 | -0.27 | -0.22 | +19.4% |
| 2025-11-06 | -0.23 | -0.23 | +2.1% |
| 2025-08-07 | -0.20 | -0.15 | +24.4% |
| 2025-05-08 | -0.20 | -0.19 | +5.0% |
| 2025-02-27 | -0.22 | -0.17 | +24.1% |
| 2024-11-14 | -0.25 | -0.23 | +8.9% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | -$19.0M | -$18.9M | — | -$18.7M | -0.31 |
| 2025-12-31 | — | -$14.1M | -$14.0M | — | -$16.7M | — |
| 2025-09-30 | — | -$14.0M | -$13.9M | — | -$16.5M | -0.23 |
| 2025-06-30 | — | -$9.3M | -$9.2M | — | -$14.7M | -0.15 |
| 2025-03-31 | — | -$10.8M | -$10.7M | — | -$12.8M | -0.19 |
| 2024-12-31 | — | — | — | — | — | — |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Lynx1 Capital Management Lp | 10.8M | $238.1M | 0.2% |
| BVF Inc. | 8.7M | $191.3M | 0.1% |
| RA Capital Management, L.P. | 7.7M | $169.8M | 0.1% |
| RTW Investments LP | 5.9M | $131.3M | 0.1% |
| FMR, LLC | 5.1M | $113.6M | 0.1% |
| Avoro Capital Advisors LLC | 1.8M | $39.8M | 0.0% |
| Toronto Dominion Bank | 1.4M | $30.9M | 0.0% |
| Troluce Capital Advisors LLC | 990.5K | $21.9M | 0.0% |
| Millennium Management Llc | 937.9K | $20.7M | 0.0% |
| Jefferies Financial Group Inc. | 712.3K | $15.8M | 0.0% |
$1.1B
5.21
1.279
8
$432.0K
1.33
9.00
0.1%
73
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-06 | $-0.32 | Pending | — |
| 2026-05-14 | $-0.26 | $-0.31 | -17.7% |
| 2026-03-05 | $-0.27 | $-0.22 | +19.4% |
| 2025-11-06 | $-0.23 | $-0.23 | +2.1% |
| 2025-08-07 | $-0.20 | $-0.15 | +24.4% |
| 2025-05-08 | $-0.20 | $-0.19 | +5.0% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($39.50, 8 analysts) | |||
| 10 | $214.60 | +$180.40 (84%) | 5.6R |
| 50 | $1,073.00 | +$902.00 (84%) | 5.6R |
| 100 | $2,146.00 | +$1,804.00 (84%) | 5.6R |
- Elevated short interest (9.00 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| ATAI | 0.342 |
| CMPS | 0.309 |
| BLSH | 0.294 |
| ARKG | 0.293 |
| IVVD | 0.288 |
| Ticker | Correlation |
|---|---|
| KMEFIC.KW | -0.177 |
| NTBLQ | -0.176 |
| PNN.L | -0.166 |
| SIM | -0.146 |
| IQCD.QA | -0.132 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.